CLINICAL TRIALS PROFILE FOR DEXILANT

All Clinical Trials for DEXILANT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00251693 ↗	Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis	Completed	Takeda	Phase 3	2005-12-01	The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
NCT00251719 ↗	Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis	Completed	Takeda	Phase 3	2005-12-01	This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
NCT00251745 ↗	Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn	Completed	Takeda	Phase 3	2005-12-01	The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00251758 ↗	Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn	Completed	Takeda	Phase 3	2005-12-01	The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
NCT00255151 ↗	Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis	Completed	Takeda	Phase 3	2006-01-01	The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
NCT00255164 ↗	Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis	Completed	Takeda	Phase 3	2006-01-01	The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).

Clinical Trial Conditions for DEXILANT

Condition Name

Condition Name for DEXILANT
Intervention	Trials
Gastroesophageal Reflux Disease	7
Esophagitis, Peptic	5
Esophagitis, Reflux	5
Gastroesophageal Reflux	5

Condition MeSH

Condition MeSH for DEXILANT
Intervention	Trials
Gastroesophageal Reflux	17
Esophagitis, Peptic	15
Esophagitis	10
Heartburn	2

Clinical Trial Locations for DEXILANT

Trials by Country

Trials by Country for DEXILANT
Location	Trials
United States	450
Mexico	14
Canada	12
India	9
Germany	8

Trials by US State

Trials by US State for DEXILANT
Location	Trials
California	18
Illinois	17
Ohio	16
Arizona	16
Texas	16

Clinical Trial Progress for DEXILANT

Clinical Trial Phase

Clinical Trial Phase for DEXILANT
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	11
Phase 2	5

Clinical Trial Status

Clinical Trial Status for DEXILANT
Clinical Trial Phase	Trials
Completed	21
Terminated	2
Unknown status	2

Clinical Trial Sponsors for DEXILANT

Sponsor Name

Sponsor Name for DEXILANT
Sponsor	Trials
Takeda	22
Vanderbilt University	2
Mayo Clinic	2

Sponsor Type

Sponsor Type for DEXILANT
Sponsor	Trials
Industry	23
Other	15